Bill shields formula makers from state courts, harming injured families

What it does

This bill moves all lawsuits over preterm infant formula injuries from state courts to federal courts, and allows any defendant to move a case to federal court without all defendants agreeing. The stated purpose is to prevent 'court shopping' and ensure uniform legal remedies, protecting the supply of specialized formula for premature babies.

Why we flagged it

The bill's operative mechanism is a jurisdictional carve-out that strips state courts of authority over formula injury claims and enables unilateral removal to federal court. While framed as supply protection, the functional effect is to shield defendants (formula manufacturers) from state-court litigation and class actions, which are historically more plaintiff-friendly.

What the text implies

• Federal courts apply stricter pleading standards (Rule 11, Twombly/Iqbal) and are generally more hostile to class certification than state courts, reducing injured families' ability to aggregate claims and recover damages.
• Removal without consent of all defendants allows manufacturers to forum-shift unilaterally, eliminating plaintiffs' choice of venue and forcing them into federal dockets where they face higher barriers to entry and discovery.
• The bill's 'supply protection' rationale is not supported by evidence that state-court litigation has actually disrupted formula manufacturing or distribution; the causal link between court jurisdiction and supply availability is asserted but unproven.
• Retroactive application to pending cases (Section 5) strips state-court jurisdiction from families already in litigation, effectively reopening settled or near-final cases and forcing re-filing in federal court at additional cost and delay.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

While the bill frames itself as protecting infant formula supply, its actual mechanism restricts injured families' access to state courts and remedies. Removing state-court jurisdiction eliminates a key forum where injured plaintiffs historically have leverage, and federal courts typically apply stricter standards for class actions and damages. Families harmed by defective formula lose a procedural advantage without clear evidence that federal jurisdiction actually protects supply.

Who stands to gain

• infant formula manufacturers (Bristol Myers Squibb, Gerber/Nestlé, Pfizer, Johnson & Johnson)
• pharmaceutical and medical device companies with similar litigation exposure

Named in the bill

Food and Drug Administration (FDA), Bristol Myers Squibb (BMY), Gerber Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), U.S. District Courts, Judicial Panel on Multidistrict Litigation, 28 U.S.C. § 1332 (diversity jurisdiction), 28 U.S.C. § 1441 (removal statute)

Where it stands

• Jun 24, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 24, 2026 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.